Ultragenyx Pharmaceutical | Pasivo Circulante



Current Liabilities Cambio Fecha
Acadia Pharmaceuticals USD 394.87M 50.92M 2024-12
Agios Pharmaceuticals USD 81.16M 38.3M 2024-12
Alnylam Pharmaceuticals USD 1.19B 34.39M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Insmed USD 297.53M 38.34M 2024-12
Ionis Pharmaceuticals USD 309.32M 4.75M 2024-12
Kyowa Hakko Kirin JPY 164.68B 8.99B 2024-12
MacroGenics USD 59.31M 1.4M 2024-09
Moderna USD 2.21B 5M 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
PTC Therapeutics USD 580.98M 29.73M 2024-12
Regeneron Pharmaceuticals USD 5.7B 2.04B 2024-12
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Ultragenyx Pharmaceutical Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.